DDW: Ozanimod active in moderate-severe UC, without cardiac signal in TOUCHSTONE trial

WASHINGTON– The oral S1P receptor modulator ozanimod is clinically active and well tolerated in patients with moderate to severe ulcerative colitis (UC), phase II study results show.

Importantly, no...